skip to primary navigationskip to content

Cambridge Institute for Medical Research

Department A-Z

Our strategy

We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Read more

Research advances

In Nature Structural and Molecular Biology, the Ron lab have uncovered a role for FICD in reversible AMPylation of the endoplasmic reticulum chaperone BiP.

Read more

Research advances

In Cell Metabolism, the Nathan lab use a forward genetic screen in human cells to reveal a novel metabolic pathway by which hypoxia-inducible factor (HIF) stability is controlled in aerobic conditions, highlighting interplay between oxygen and metabolic sensing.

Read more

Call for new investigators

The Cambridge Institute for Medical Research (CIMR) seeks to recruit exceptional researchers at all career stages.

Read more

Research news

A collaboration between the lab of Lucy Raymond, UCL Great Ormond Street Institute of Child Health and the NIHR Rare Disease Bioresource has identified a new genetic movement disorder (KMT2B-related dystonia) that can be treated with deep brain stimulation.

Read more

Potential haemophilia treatment

A new strategy that might be used to treat haemophilia, arising from a collaboration between the Huntington lab and Trevor Baglin at Addenbrooke's Hospital, is now being progressed by the start-up company ApcinteX.

Read more

New approaches to type 1 diabetes

Clinical research led by Frank Waldron-Lynch suggests that limiting autoimmune damage against insulin-producing cells may be an effective approach to treating type 1 diabetes.

Read more

A unique partnership between basic and clinical research, aiming to understand the cellular basis of disease

New publications


Raymond lab (Nature Genet. 2016)

Identification of a KMT2B-linked movement disorder.


Rubinsztein lab (Nature Comm. 2016)

Chaperone inhibition of protein aggregation via autophagy.


Ron lab (Nature Struct. Mol. Biol. 2016)

FICD-mediated de-AMPylation of BiP ER chaperone.


Huntington lab (Blood 2016)

Engineered serpins for rescue of thrombin generation.


Lehner lab (eLife 2016)

Vif targeting of PP2A in HIV infection.


Nathan lab (Cell Met. 2016)

Coordinated oxygen and metabolic sensing.


Lehner lab (Cell Rep. 2016)

ATF7IP is a key effector of the HUSH complex.